Page last updated: 2024-10-27

gabapentin and Impairment, Light Touch Sensation

gabapentin has been researched along with Impairment, Light Touch Sensation in 3 studies

Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.
gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.

Research Excerpts

ExcerptRelevanceReference
"Patients reported significant pain relief in favor of gabapentin in the first period."9.11Randomised controlled trial of gabapentin in Complex Regional Pain Syndrome type 1 [ISRCTN84121379]. ( Kessels, AH; Stomp-van den Berg, SG; van de Vusse, AC; Weber, WE, 2004)
"Patients reported significant pain relief in favor of gabapentin in the first period."5.11Randomised controlled trial of gabapentin in Complex Regional Pain Syndrome type 1 [ISRCTN84121379]. ( Kessels, AH; Stomp-van den Berg, SG; van de Vusse, AC; Weber, WE, 2004)
"Many patients with neuropathic pain have coexistent sensory deficits."1.31Case reports - reversal of sensory deficit associated with pain relief after treatment with gabapentin. ( Chong, MS; Hanna, M; Smith, TE, 2002)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
van de Vusse, AC1
Stomp-van den Berg, SG1
Kessels, AH1
Weber, WE1
Povedano, M1
Gascón, J1
Gálvez, R1
Ruiz, M1
Rejas, J1
Chong, MS1
Smith, TE1
Hanna, M1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Treatment of Complex Regional Pain Syndrome With Once Daily Gastric-Retentive Gabapentin (Gralise)[NCT01623271]5 participants (Actual)Interventional2013-05-31Terminated (stopped due to Due to limited population of research participants.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Visual Analog Scale (VAS) at Visit 3

Subjects rated their pain using the VAS at visit 3, which was the last day of their maintenance phase. After this visit, subjects begin to taper the gralise. The VAS is subject reported on a scale of 0-10 with 0 being no pain and 10 being the worst pain they can imagine. Results reported are an average of the 3 subjects who completed visit 3. (NCT01623271)
Timeframe: At visit 3

Interventionunits on the VAS (Mean)
CRPS I Pain Subjects3.67

Trials

1 trial available for gabapentin and Impairment, Light Touch Sensation

ArticleYear
Randomised controlled trial of gabapentin in Complex Regional Pain Syndrome type 1 [ISRCTN84121379].
    BMC neurology, 2004, Sep-29, Volume: 4

    Topics: Adult; Aged; Amines; Analgesics; Cross-Over Studies; Cyclohexanecarboxylic Acids; Double-Blind Metho

2004

Other Studies

2 other studies available for gabapentin and Impairment, Light Touch Sensation

ArticleYear
Cognitive function impairment in patients with neuropathic pain under standard conditions of care.
    Journal of pain and symptom management, 2007, Volume: 33, Issue:1

    Topics: Adult; Aged; Amines; Analgesics; Cognition Disorders; Cohort Studies; Cyclohexanecarboxylic Acids; F

2007
Case reports - reversal of sensory deficit associated with pain relief after treatment with gabapentin.
    Pain, 2002, Volume: 96, Issue:3

    Topics: Acetates; Aged; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobuty

2002